Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women with Breast Cancer Receiving Chemotherapy

Description

This study evaluates the relationship between alterations in the GI microbiome and GI inflammation on symptom burden in women with breast cancer receiving chemotherapy.

Conditions

Anatomic Stage I Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates the relationship between alterations in the GI microbiome and GI inflammation on symptom burden in women with breast cancer receiving chemotherapy.

Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women with Breast Cancer Receiving Chemotherapy

Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women with Breast Cancer Receiving Chemotherapy

Condition
Anatomic Stage I Breast Cancer AJCC V8
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Mayo Clinic in Arizona, Scottsdale, Arizona, United States, 85259

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female with a new diagnosis of breast cancer (stage I-III)
  • * Age 20 or older
  • * Able to read and write in English
  • * Chemotherapy naive and beginning the first cycle of moderately or highly emetogenic chemotherapy (For example, Taxotere + cyclophosphamide treatment +/- trastuzumab). Patients who have not received chemotherapy for five years or more are considered chemotherapy naive
  • * Metastatic disease
  • * Cognitive impairment, based on clinician assessment, that would prevent completing measures
  • * Concurrent radiation therapy or radiation therapy within the last three months
  • * GI co-morbidities (i.e., irritable bowel syndrome, gastroesophageal reflux disease) or bowel surgery within the last three months
  • * A stoma preventing stool collection from the large intestine (i.e., ileostomy)

Ages Eligible for Study

20 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Komal P. Singh, PhD, RN, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2026-03-30